0001266806 false00012668062026-11-152026-11-15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 15, 2026

 

 

Vivani Medical, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36747

 

02-0692322

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

1350 S. Loop Road

Alameda, California

 

94502

(Address of principal executive offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (415) 506-8462

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

VANI

 

The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 



Item 1.01 Entry into a Material Definitive Agreement.

Private Placement

Vivani Medical, Inc. (the “Company”) entered into a Share Purchase Agreement, dated November 15, 2026 (the “Purchase Agreement”), with entities affiliated with Gregg Williams, Chairman of the Company’s board of directors, and Aaron Mendelsohn, another member of the Company’s board of directors (collectively, the “Purchasers”) for the purchase of an aggregate of 5,049,506 shares of common stock, par value of $0.0001 per share (“Common Stock”) of the Company at a purchase price of $1.01 per share (the “Private Placement Shares”), the last reported sale price of the Common Stock on November 13, 2026.  This private placement of Common Stock resulted in gross proceeds of approximately $5.1 million to the Company.  No warrants or discounts were provided and no placement agent or investment banking fees were incurred in connection with the private placement.

The Private Placement Shares will be issued pursuant to an exemption from registration under Rule 506 of Regulation D, which is promulgated under the Securities Act of 1933, as amended (the “Securities Act”).  The Company relied on this exemption from registration based in part on representations made by each of the Purchasers.

The above description of principal terms of the Purchase Agreement is qualified in its entirety by reference to that agreement attached hereto as Exhibit 10.1.

Item 3.02 Unregistered Sales of Equity Securities.

Pursuant to the private placement described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated by reference into this Item 3.02 in its entirety, the Company has agreed to sell the Private Placement Shares to “accredited investors,” as that term is defined in the Securities Act, in reliance on the exemption from registration afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act and corresponding provisions of state securities or “blue sky” laws.  Each Purchaser represented that it is acquiring the Private Placement Shares for investment only and not with a view towards, or for, resale in connection with, the public sale or distribution thereof.  Accordingly, the Private Placement Shares have not been registered under the Securities Act and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state securities laws.  Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of common stock or other securities of the Company.

Item 7.01 Regulation FD Disclosure

Private Placement Press Release

On November 16, 2026, the Company issued a press release titled “Vivani Medical Announces Private Placement Equity Offering.” The press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. 

Corporate Presentation

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. These slides are attached to this Current Report as Exhibit 99.2 and are incorporated by reference herein. The Company is also posting to the “Investors” portion of its website a copy of its current corporate slide presentation. The slides speak as of the date of this Current Report on Form 8-K. While the Company may elect to update the slides in the future or reflect events and circumstances occurring or existing after the date of this Current Report, the Company specifically disclaims any obligation to do so.

The information contained in this Current Report on Form 8-K under Item 7.01, including the attached Exhibits 99.1 and 99.2, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section.  The information contained in this Current Report on Form 8-K under Item 7.01, shall not be incorporated by reference into any filing under the Securities Act, or any filing under the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1*

Share Purchase Agreement, dated as of November 15, 2026.

99.1

Press Release issued November 16, 2026.

99.2

Vivani Medical, Inc. slide presentation dated November 16, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

* Filed herewith.

 



SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VIVANI MEDICAL, INC.

 

 

 

Date: November 16, 2026

By:

/s/ Donald Dwyer

 

Name:

Donald Dwyer

 

Title:

Chief Business Officer